Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience.
Shinya TsuboiTatsuya HayamaKatsuhiro MiuraAkihiro UchiikeDaisuke TsutsumiTakashi YamauchiYoshihiro HattaSusumu OotsukaPublished in: Journal of pharmaceutical health care and sciences (2023)
Younger age (< 55 years) was significantly associated with a higher risk of PIBP among patients receiving chemotherapy with a ≥ 10% risk of FN. Therefore, oncologists should meticulously formulate management plan for PIBP in younger patients after administering pegfilgrastim.
Keyphrases
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- chemotherapy induced
- locally advanced
- peritoneal dialysis
- risk factors
- prognostic factors
- pain management
- high glucose
- squamous cell carcinoma
- bone mineral density
- patient reported outcomes
- spinal cord injury
- drug induced
- palliative care
- advanced cancer